Oklahoma State University is a Tier 1 research university offering a full range of degrees in Engineering, Biotechnology, Agriculture and Medicine | Oklahoma State University is a land grant institution, focused on improving our quality of life by bringing new technologies, processes, research, and medicines to the marketplace. OSU is showcasing several technologies that are at the right stage for partnering at BIO International. Cowboy Enterprises is the orange-plated, premium conduit for Industry and Oklahoma State University engagement. Meeting needs for research, technology transfer, lab & research facilities, research park, as well as mutually beneficial collaborations, Cowboy Enterprises would like to show you how OSU Orange is the answer. Our mission runs parallel with that of Oklahoma State University’s land grant mission of taking university research from “CAMPUS TO COMMUNITY”. Collaborating with research Cowboy Innovations and OSU’s researchers to identify technologies that have commercial interest and viability, and progress them to later stages of development that will meet market needs. The College of Veterinary Medicine is a major research center on campus. We have invested in state of the art laboratory facilities to accomplish our mission of service to companion animal, livestock, and human health and well-being. These laboratories are designed to the highest standards for conduct of infectious disease and toxicology research and meet all federal and state regulatory guidelines. OSU-CHS Tulsa (Center for Health Sciences) has just brought on-line a new facility that is centrally managed for FDA Clinical Trials (non-ontological). OSU-CHS has conducted clinical trials since the early 2000’s with an average of 10 to 15 clinical trials a year. Over the last four years, there have been a total of 16 FDA-regulated clinical trials. It is important to note that the clinical trials range in time frame from 1 to 15 years (thus overlapping between the years for the total number of trials). The OSU-CHS clinical trials unit supports clinical trial operations for our investigators in Tulsa, within our outpatient clinical practice areas. Active clinical trials include Pediatrics, Internal Medicine, and Internal Medicine specialty services (Ryan White Center). Oklahoma Center for Respiratory and Infectious Diseases (OCRID) OCRID is a focal point for expanding respiratory infectious disease research in Oklahoma. OCRID engages in critical research on respiratory infectious diseases with a focus on the influenza virus, respiratory syncytial virus, and respiratory bacterial and fungal infections, and now COVID-19. The interdisciplinary projects in OCRID cover therapeutics, vaccine, diagnostics, disease pathogenesis, nutrition, and bioengineering. OCRID provides training and mentoring to junior faculty and the next-generation of scientists, promotes collaboration among scientists throughout the region, recruits new faculty to member institutions, and strengthens biomedical research infrastructure. Institute for Translational and Emerging Research in Advanced Comparative Therapy (INTERACT) Located in the College of Veterinary Medicine, INTERACT leads the one-health mission of OSU by bringing together clinicians, scientists and researchers involved in fundamental discovery, industry and foundations under one roof. INTERACT is endowed with state-of-the art research and clinical infrastructure, and dedicated personnel. We are currently running several clinical trials. We welcome researchers from across the nation to collaborate and participate in our preclinical projects or clinical trials. The Center for Health Systems Innovation (CHSI) creates solutions to transform patient care with an intensive focus on rural primary care and communities. We design, test, and implement solutions to clearly defined problems in rural primary care clinics and hospital settings. Additionally, CHSI focuses on mental health and its impact on outcomes. The National Center for Wellness and Recovery (NCWR), part of Oklahoma State University Center for Health Services, is a leading medical educator and healthcare provider. Our vision is to eliminate addiction through research and excellence in patient care. The NCWR is looking for partners to advance the treatment and prevention of addiction along with innovative therapies for pain. Rural healthcare providers face patients with more chronic diseases than other populations of the same age. Therefore, we focus on the following diseases: Heart disease, Stroke, Hypertension, Diabetes, Respiratory, and Addiction. Human Performance and Nutrition Research Institute (HPNRI) Oklahoma State University is harnessing the university’s cutting-edge research expertise in human performance and nutrition science, coupling it with advanced knowledge from our elite strength and conditioning staff and leveraging it with leading industry partner relationships to create a first-of-its-kind, university-based research institute. Oklahoma Disease Diagnostic Laboratory (OADDL) Promoting the overall well-being of animal health through veterinary diagnostic testing, instruction of professional students, and research in diseases of economic importance to Oklahoma and beyond. National Center for Veterinary Parasitology Launched in 2009, the National Center for Veterinary Parasitology (NCVP) at Oklahoma State University’s Center for Veterinary Health Sciences is helping carry the fight against parasites and vectors, such as mosquitoes, ticks, and the organisms they transmit. These foes attack humans, animals and our food supply. The National Center for Veterinary Parasitology is the only one of its kind and began with the financial backing of the Kirkpatrick Foundation, Novartis Animal Health, Bayer Animal Health and Merial. Since many of these parasites are zoonotic and can cause disease in people, so identifying and treating the infections are particularly important. The center also provides egg per gram counts for horses and cattle, allowing veterinarians to tailor integrated parasite management programs and monitor treatment effectiveness. Comparative Metabolic Lab The Comparative Metabolism laboratory investigates glucose metabolism during metabolic diseases (e.g., diabetes, insulin resistance and obesity) and novel metabolic therapeutic strategies that could benefit both veterinary and human patients. Diabetes and obesity, global epidemic diseases, are significant risk factors for cardiovascular and pulmonary diseases. One of the major pathogenic processes underlying these metabolic diseases results from a deficit of insulin production or action, with dysfunctional glucose uptake into insulin-sensitive tissues. Core Facilities Genomics and Proteomics Center: Providing DNA and Protein sequencing and genomic and proteomic analyses across the campus. DNA Protein Core Facility: The Facility performs specialized biochemical analysis, manages a battery of multi-user equipment including mass spec, provides technical expertise, and vends specialized biochemicals, to analyze structure and function of DNA and proteins. Oklahoma Statewide Shared Nuclear Magnetic Resonance Facility: NMR is an extremely versatile and robust spectroscopic method for studies of biomolecules in solution. Indeed, this is the only spectroscopic technique that provides detailed structural and dynamic information of a biomolecule in its native environment. The Facility allows users including faculty members, post-doctoral scientists, graduate and undergraduate students in all major academic institutions, 4-year undergraduate colleges as well as scientists working in industries in Oklahoma and the surrounding region (Kansas and Texas) to conduct research investigations. We welcome scientists from all parts of the country to take advantage of this state-of-the-art facility.
Novogene America
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene is a global leader in Next-Generation Sequencing (NGS), Proteomics, and Metabolomics services, empowering researchers and organizations with cutting-edge multi-omics solutions. Since our founding in March 2011, we have remained at the forefront of innovation, delivering world-class services to advance discoveries in life sciences, healthcare, and beyond. With state-of-the-art laboratories and operations across the United States, the United Kingdom, Germany, China, Singapore, and Japan, Novogene has established a strong global presence to support scientific advancements worldwide.
Novalis VC
Novalis Biotech is an early stage venture capital investor in life sciences. We welcome innovative concepts in TechBio and aim to support their development already at the state of incorporation. Our investment focus is “enabling technologies” in life sciences. We strongly believe in capital light platform technology and close interaction with customers already early in the life of the company. Focus areas are: innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health. We focus on early-stage start-ups, from (pre-)seed stage to series A, and support their evolution by providing funding, sharing our professional and academic connections, and helping to shape the business strategy in order to create value for all stakeholders.
Nia Health GmbH
Nia Health is a digital health technology company specializing in advanced medical research solutions, emerging from the interdisciplinary research ecosystem of Charité – Universitätsmedizin Berlin, a globally recognized center for medical innovation. Our portfolio includes CE-certified medical device applications for chronic inflammatory skin conditions, specifically developed for patients with atopic dermatitis and psoriasis. These medical-grade digital monitoring platforms provide certified medical documentation and patient management tools, setting new standards in digital therapeutics. Our proprietary platform combines machine vision AI and advanced machine learning to revolutionize medical research and patient monitoring. By delivering objective, quantifiable assessments across multiple medical domains, we enable precise dermatological, immunological, and pharmaceutical research insights. Key technological innovations include: – AI-powered severity classification – Real-time disease progression tracking – Smartphone and web-based monitoring tools – Predictive treatment response analytics The platform offers comprehensive solutions for pharmaceutical companies, enabling: – Precise clinical trial patient screening – Objective treatment effectiveness measurement – Automated data collection – Privacy-compliant patient monitoring Our machine vision technology can assess conditions across dermatology, wound management, oncology, and infectious disease tracking, providing unprecedented insights into disease progression and treatment responses. By seamlessly integrating advanced imaging technologies with sophisticated data analytics, Nia Health delivers scalable digital solutions that enhance medical decision-making, optimize research processes, and drive innovation in healthcare technology. Driven by an interdisciplinary approach combining medical expertise and cutting-edge technological innovation, we are committed to transforming medical research through intelligent, data-driven solutions.
NewBiologix
NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines. NewBiologix is committed to improve the generation and production of viral vectors used in gene and cell therapies by combining innovative and proprietary bioinformatics platform with advanced R&D experimentation. Next-generation sequencing (NGS)-based genome characterization will be used to develop an innovative and proprietary bioinformatics platform that will help cell line engineering through a combination of exceptionally in-depth datasets, sophisticated genomic analyses, and advanced R&D experimentation. NewBiologix’ technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines engineered to be readily adaptable to meet the viral vector demands and requirements over a full range of products. With a strong Series A financing and an experienced start-up team established, NewBiologix anticipates cell line prototypes will be ready for beta testing with key collaborators by 2024 with the goal of commercially available viral production cell line lines by 2025. | NewBiologix is a technology innovation company developing proprietary platforms for the improved production of viral vectors used in gene and cell therapies. The company offers best-in-class rAAV variant screening, proprietary engineered HEK293 cell line programs, and next-generation sequencing (NGS) services including PacBio, Illumina, Nanopore, and Bionano. Our suite of technologies aims to help biopharmaceutical companies develop transformative gene therapies faster, safer, and at scale. | NewBiologix SA is a biotechnology company developing Swiss-engineered solutions for gene and cell therapy production. Specializing in cell line engineering, the company offers advanced cell lines and a genomic analytical platform, including the Xcell Engineered HEK293 Cell Line, custom high-quality AAV production, and cellular and viral genomic characterization with integrated bioinformatics. Our expertise enables partners to develop and scale gene therapies faster, while ensuring they are safer and more reliable.
Nationwide Children’s Hospital
The Division of Pulmonary, Sleep Medicine and Cystic Fibrosis at Nationwide Children’s Hospital provides the highest quality clinical care for children and adults with congenital respiratory disorders, including cystic fibrosis, advanced lung disease, sleep-related breathing disorders and more. Our providers care for patients approaching and following lung/heart-lung transplant and those managing long-term mechanical ventilation. We are proud of the care we provide to children with respiratory disease, and this was acknowledged again this year by U.S. News & World Report as we have remained a top 10 pediatric pulmonary department since 2012! | At Nationwide Children’s Hospital, we understand the importance of translating innovative work beyond our walls and into the world. New technologies drive economic development in our local, national, and global ecosystem and most importantly, improve pediatric care. The Office of Technology Commercialization exists to ensure that the necessary partnerships are in place to execute this important function. Nationwide Children’s Hospital is one of America’s largest pediatric hospitals, an international leader in research, and is ranked in all 10 specialties on U.S. News & World Report’s 2023-24 “America’s Best Children’s Hospitals” list. In addition, according to the Children’s Hospital Association, Nationwide Children’s is the #1 provider of pediatric surgery in the country. The Abigail Wexner Research Institute at Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving discoveries into the marketplace. The hospital’s innovators, stationed in more than 800,000 square feet of dedicated research space, are committed to enhancing the health of children by engaging in high-quality, cutting-edge research according to the highest scientific and ethical standards while advancing life-saving therapies to children everywhere. The Office of Technology Commercialization at Nationwide Children’s guides ideas to solutions by offering expertise in technology transfer and facilitating partnerships between inventors and industry to bring discoveries to patients, clinicians and scientists around the world. Our resourceful team guides Nationwide Children’s clinicians, researchers, and partners through complex processes with creative solutions. This ranges from therapeutics, biomarkers, diagnostic tools, research and clinical tools, and medical devices. Some of our successes include first-of-their-kind gene therapies, Zolgensma and Elevidys – FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) – and medical devices like the Comfort Collar or the Endoscopic Retrieval Device. Nationwide Children’s Hospital, located in Columbus, Ohio and with over 16,000 employees, is leading a bold journey to best outcomes for children everywhere. | The Nationwide Children’s Hospital Office of Technology Commercialization (OTC) guides ideas to solutions by offering expertise in technology transfer and facilitating partnerships between inventors and industry to bring discoveries to patients, clinicians and scientists around the world. Our resourceful team guides inventors and partners through complex processes with creative solutions. This ranges from therapeutics, including the approved, first-of-their-kind gene therapies – Zolgensma and Elevidys, FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) – to biomarkers, diagnostic tools and clinical tools – such as the Comfort Collar, designed to prevent pressure wounds around tracheostomy tubes – to outside partners to benefit patients, the local community and the general public. As a result, the Abigail Wexner Research Institute at Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving discoveries into the marketplace. The hospital’s physicians and researchers are dedicated to enhancing the health of children by engaging in high-quality, cutting-edge research according to the highest scientific and ethical standards while advancing life-saving therapies to children everywhere. We encourage all interested entrepreneurs and potential licensing partners to stop by the Ohio Pavilion (Booth No. 1865) to discuss our many available preclinical and clinical technologies, ranging from early-stage innovations to market-ready products. Our portfolio of over 200 available technologies developed by our innovative researchers and clinicians at Nationwide Children’s Hospital is diverse and ever-growing. | The Office of Technology Commercialization (OTC) at Nationwide Children’s Hospital supports the translation of innovative research into real-world healthcare solutions. Working closely with clinicians, researchers, and industry partners, OTC advances intellectual property development, licensing, and startup formation to bring pediatric-focused technologies to market. OTC also collaborates closely with the Nationwide Children’s Innovation Center to foster cross-disciplinary innovation and accelerate the development of novel solutions from concept through commercialization. Nationwide Children’s Hospital is consistently ranked among the top 10 children’s hospitals in the nation by U.S. News & World Report, earning the “Honor Roll” distinction for 12 consecutive years as of 2025. It is also the #1 ranked pediatric hospital in Ohio and the Midwest and is consistently among the top NIH-funded pediatric research institutions in the United States, reflecting its national leadership in biomedical discovery and translational science. Together, Nationwide Children’s, the OTC and Innovation Center drive collaboration and commercialization efforts that accelerate the development of life-changing therapies, devices, and diagnostics for children worldwide.
National Health Research Institutes
The National Health Research Institutes (NHRI) is a non-profit organization and a government funded mission-oriented research institution in Taiwan. NHRI dedicates to the medical and health research concerning the general well-being of the people in Taiwan. NHRI tackles important diseases in Taiwan through basic and translational research, and provides evidence based recommendation to the government to help guide timely health policy. NHRI acts as a think tank for vaccine production, biomedical engineering and pharmaceutical industries in Taiwan. | The National Health Research Institutes (NHRI) is a non-profit foundation established by the government with its organization charter created by an Act of Congress (Legislative Yuan) and signed in 1995 by President Teng-hui Lee. Being an autonomous research organization under the supervision of the Department of Health, Executive Yuan, the NHRI is dedicated to the enhancement of medical research and the improvement of health care in this country. Scientists at the NHRI conduct mission-oriented medical research and investigate many aspects of the basic biomedical sciences, as well as specific diseases. These range from the common problems such as aging, cancer, infectious diseases, mental disorders, occupational diseases, to health policy. It is our hope that the knowledge, experience, and facilities at the NHRI will become important resources to the whole nation in understanding, preventing, and curing diseases. The NHRI has been established to serve the following purposes: To plan the overall directions of national science and technology development in health and medical care; To coordinate, integrate, and support research activities undertaken by medical institutions in this country; To further educate and train young scientists and physicians; To establish an objective and fair system for reviewing and assessing research projects and their progress; To facilitate the exchange of information and to promote domestic and international cooperation. It is anticipated that both public and private sector efforts of the NHRI will help achieve excellence in medical research in Taiwan.
Montgomery County Economic Development Corporation
The Montgomery County Economic Development Corporation serves as the official economic development entity for Montgomery County, Maryland to accelerate business development, attraction, retention and expansion in key industry sectors while advancing equitable and inclusive economic growth. We operate as a 501(c)(3) nonprofit public-private partnership, funded by Montgomery County. | The Montgomery County Economic Development Corporation serves as the official economic development entity for Montgomery County, Maryland to accelerate business development, attraction, retention and expansion in key industry sectors while advancing equitable and inclusive economic growth.